Business Description
Roquefort Therapeutics PLC
ISIN : GB00BMDQ2T15
Description
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.98 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.36 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.23 | |||||
| 9-Day RSI | 36.52 | |||||
| 14-Day RSI | 40.61 | |||||
| 6-1 Month Momentum % | -15.79 | |||||
| 12-1 Month Momentum % | -44.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.79 | |||||
| Quick Ratio | 0.79 | |||||
| Cash Ratio | 0.69 | |||||
| Days Payable | 4227.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -967 | |||||
| Net Margin % | -872.5 | |||||
| FCF Margin % | -685 | |||||
| ROE % | -27.36 | |||||
| ROA % | -23.97 | |||||
| ROIC % | -26.57 | |||||
| ROC (Joel Greenblatt) % | -3368 | |||||
| ROCE % | -28.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 18.25 | |||||
| PB Ratio | 0.96 | |||||
| EV-to-EBIT | -2.95 | |||||
| EV-to-EBITDA | -2.96 | |||||
| EV-to-Revenue | 24.84 | |||||
| EV-to-FCF | -3.63 | |||||
| Earnings Yield (Greenblatt) % | -33.9 | |||||
| FCF Yield % | -27.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roquefort Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 0.2 | ||
| EPS (TTM) (£) | -0.012 | ||
| Beta | -0.59 | ||
| Volatility % | 35.29 | ||
| 14-Day RSI | 40.61 | ||
| 14-Day ATR (£) | 0.00434 | ||
| 20-Day SMA (£) | 0.04034 | ||
| 12-1 Month Momentum % | -44.83 | ||
| 52-Week Range (£) | 0.033 - 0.095 | ||
| Shares Outstanding (Mil) | 135.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roquefort Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roquefort Therapeutics PLC Stock Events
| Event | Date | Price(£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Roquefort Therapeutics PLC Frequently Asked Questions
What is Roquefort Therapeutics PLC(LSE:ROQ)'s stock price today?
The current price of LSE:ROQ is £0.04. The 52 week high of LSE:ROQ is £0.10 and 52 week low is £0.03.
When is next earnings date of Roquefort Therapeutics PLC(LSE:ROQ)?
The next earnings date of Roquefort Therapeutics PLC(LSE:ROQ) is 2025-04-25 Est..
Does Roquefort Therapeutics PLC(LSE:ROQ) pay dividends? If so, how much?
Roquefort Therapeutics PLC(LSE:ROQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers